A study found that 9 in 10 adults with chronic kidney disease (CKD) are not aware of their diagnosis. Primary care providers should improve screening for CKD since only 40% of those with diabetes and insurance receive appropriate testing. New drugs, such as SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists, have considered the benefits of broadened screening. Stanford researchers found that the use of SGLT2 inhibitors substantially improved life expectancy by two years and reduced the need for dialysis or transplant. These findings indicate that the USPSTF should reconsider their 2012 decision not to recommend universal CKD screening, as broadening CKD screening could be more cost-effective than previously thought.
Source link
Why Is Kidney Disease So Often Missed?
